secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097546
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene enters $100M at-the-market equity facility with Leerink Partners
-----------------------------------------------------------------------

- New Sales Agreement with Leerink Partners for up to $100M in common shares via at-the-market offerings.
- Prior Open Market Sale Agreement with Jefferies LLC terminated on March 6, 2026; no shares sold and no penalties.
- Leerink will receive a commission of up to 3.0% of gross proceeds; Company may reimburse certain expenses.
- Shares will be sold under Rule 415(a)(4); Company not obligated to sell any shares.
- No shares offered or sold in Canada under the new agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/0001193125-26-097546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/engn-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer